OncoTherapy Science, Carna Biosciences, CrystalGenomics to Collaborate in Development of Low-molecular Drug for Cancer.Tokyo, Japan, Feb 1, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - OncoTherapy Science (OTS See Office of Thrift Supervision. ) announced on February 1 that it has signed a joint research agreement with Carna Biosciences (CARNA) and CrystalGenomics (CG). The three companies will collaborate in searching low-molecular compounds that inhibit the activities of two different cancer-specific protein kinases protein kinase /pro·tein ki·nase/ (pro´ten ki´nas) an enzyme that catalyzes the phosphorylation of serine, threonine, or tyrosine groups in enzymes or other proteins, using ATP as a phosphate donor. possessed by OTS. Specifically, CARNA will be in charge of protein expression, assay formulation and screening while CG will handle virtual screening of compounds, compound library creation and X-ray crystallographic crys·tal·log·ra·phy n. The science of crystal structure and phenomena. crys  tal·log analysis. Further, using the newly-identified low-molecular compounds, the three companies will strive to develop compound candidates for cancer treatment. The partners will co-own rights to the new compounds, but OTS will be in charge of commercializing them. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion